MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

Merck (MRK) announced positive topline data from two pivotal phase III studies evaluating the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in virologically suppressed adults with HIV-1 infection.The phase III MK-8591A-051 and MK-8591A-052 studies evaluated DOR/ISL (100 mg/0.25 mg) in adults with HIV-1 infection who are on different antiretroviral therapy regimens like baseline antiretroviral therapy and bictegravir/emtricitabine/tenofovir alafenamide, ...